All In Biotech

Drug Trial Radar · NCT05071716

Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 524 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

524

Actual

Start

Apr 7, 2022

Primary completion

Dec 23, 2025

Study completion Dec 23, 2025

Sponsor

Lead sponsor
Bausch Health Americas, Inc.Industry
Sponsor type
Industry
First posted
Oct 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study RNLC3131 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in liver cirrhosis, defined by the presence of medically controlled ascites.

Conditions

  • Hepatic Encephalopathy

Interventions

  • Rifaximin SSDDrug

    Rifaximin Solid Soluble Dispersion Immediate Release Twice Daily

  • PlaceboDrug

    Placebo Twice Daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Event of Overt Hepatic Encephalopathy (OHE) Requiring Medical Intervention in the Hospital/Emergency Room (ER)/Emergency Department (ED)/Clinic or DeathTime frame: 72 weeks

Locations

150 sites in 4 countries. Site status is shown where the registry gives one.

  • Bausch Site 182

    Dothan, Alabama

  • Bausch Site 129

    Chandler, Arizona

  • Bausch Site 103

    Peoria, Arizona

  • Bausch Site 180

    Phoenix, Arizona

  • Bausch Site 153

    Phoenix, Arizona

  • Bausch Site 248

    Tempe, Arizona

  • Bausch Site 222

    Tucson, Arizona

  • Bausch Site 150

    Little Rock, Arkansas

  • Bausch Site 164

    Bakersfield, California

  • Bausch Site 196

    Chula Vista, California

  • Bausch Site 226

    Chula Vista, California

  • Bausch Site 174

    Escondido, California

  • Bausch Site 163

    Fresno, California

  • Bausch Site 242

    Garden Grove, California

  • Bausch Site 115

    La Jolla, California

  • Bausch Site 141

    Lancaster, California

  • Bausch Site 140

    Los Angeles, California

  • Bausch Site 189

    Los Angeles, California

  • Bausch Site 227

    Orange, California

  • Bausch Site 199

    Pasadena, California

  • Bausch Site 119

    Redwood City, California

  • Bausch Site 102

    Rialto, California

  • Bausch Site 177

    San Diego, California

  • Bausch Site 171

    San Francisco, California

  • Bausch Site 214

    San Jose, California

  • Bausch Site 183

    Upland, California

  • Bausch Site 143

    Englewood, Colorado

  • Bausch Site 212

    Littleton, Colorado

  • Bausch Site 151

    Bristol, Connecticut

  • Bausch Site 220

    Bradenton, Florida

  • Bausch Site 257

    Cape Coral, Florida

  • Bausch Site 197

    Cutler Bay, Florida

  • Bausch Site 249

    Fort Myers, Florida

  • Bausch Site 173

    Hialeah, Florida

  • Bausch Site 238

    Hialeah Gardens, Florida

  • Bausch Site 235

    Hollywood, Florida

  • Bausch Site 211

    Homestead, Florida

  • Bausch Site 139

    Inverness, Florida

  • Bausch Site 138

    Jacksonville, Florida

  • Bausch Site 241

    Lakewood Rch, Florida

Showing 40 of 150 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.